Intestinal Research

Original Article

IBD

Concomitant ankylosing spondylitis can increase the risk of biologics or small molecule therapies to control inflammatory bowel disease: Yu Kyung Jun, Hyuk Yoon, Seong-Joon Koh, A Hyeon Kim, Kwang Woo Kim, Jun Won Park, Hyun Jung Lee, Hyoun Woo Kang, Jong Pil Im, Young Soo Park, Joo Sung Kim, on behalf of Seoul National University Inflammatory Bowel Disease Research Network (SIRN); Intest Res 2023;21(2):244-251. Published online August 8, 2022; DOI: https://doi.org/10.5217/ir.2022.00057

Abstract PDF Supplementary Material PubReader ePub

Background/Aims
Patients with inflammatory bowel disease (IBD) are diagnosed with ankylosing spondylitis (AS) often. However, the disease course of patients with both IBD and AS is not well understood. This study aims to evaluate the effect of concomitant AS on IBD outcomes.
Methods
Among the 4,722 patients with IBD who were treated in 3 academic hospitals from 2004 to 2021, 55 were also diagnosed with AS (IBD-AS group). Based on patients’ electronic medical records, the outcomes of IBD in IBD-AS group and IBD group without AS (IBD-only group) were appraised.
Results
The proportion of patients treated with biologics or small molecule therapies was significantly higher in IBD-AS group than the proportion in IBD-only group (27.3% vs. 12.7%, P= 0.036). Patients with both ulcerative colitis and AS had a significantly higher risk of biologics or small molecule therapies than patients with only ulcerative colitis (P< 0.001). For univariable logistic regression, biologics or small molecule therapies were associated with concomitant AS (odds ratio, 4.099; 95% confidence interval, 1.863–9.021; P< 0.001) and Crohn’s disease (odds ratio, 3.552; 95% confidence interval, 1.590–7.934; P= 0.002).
Conclusions
Concomitant AS is associated with the high possibility of biologics or small molecule therapies for IBD. IBD patients who also had AS may need more careful examination and active treatment to alleviate the severity of IBD.

Citations

Citations to this article as recorded by

Author's Reply: “Association of early antibiotic use with risk of ulcerative colitis”
Junseok Park, Sungjin Woo, Seong-Joon Koh
Digestive and Liver Disease.2025; 57(3): 795. CrossRef
Risk of all-cause and cause-specific mortality associated with immune-mediated inflammatory diseases in Korea
Oh Chan Kwon, See Young Lee, Jaeyoung Chun, Kyungdo Han, Yuna Kim, Ryul Kim, Min-Chan Park, Jie-Hyun Kim, Young Hoon Youn, Hyojin Park
Frontiers in Medicine.2023;[Epub] CrossRef

10,137 View
466 Download
3 Web of Science
2 Crossref

Case Report

Crohn's disease with ankylosing spondylitis in an adolescent patient who had undergone long ileo-colonic anastomosis for Hirschsprung's disease as an infant: Ha Yeon Kim, Tae Wook Kim; Intest Res 2017;15(1):133-137. Published online January 31, 2017; DOI: https://doi.org/10.5217/ir.2017.15.1.133

Abstract PDF PubReader ePub

Crohn's disease (CD) is a chronic, idiopathic, inflammatory disorder of the gastrointestinal tract. In rare cases, CD has been associated with Hirschsprung's disease (HD); however, the underlying pathophysiology of this and other comorbidities is not yet fully understood. In this report, we describe the case of a 17-year-old patient who was diagnosed with both CD and ankylosing spondylitis (AS), having undergone a long ileo-colonic anastomosis to treat HD at 12 months of age. To our knowledge, this is the first documented case of CD combined with AS in a patient with HD.

Citations

Citations to this article as recorded by

The Frequency and Characteristics of Inflammatory Bowel Disease in Pediatric Patients with Hirschsprung's Disease: A Case-Control Study
Naghi Dara, Niloofar Ziba, Leily Mohajerzadeh, Yasaman Zarinfar, Arshia Dara, Amirhossein Hosseini, Saleheh Tajalli, Nathalia Sernizon Guimarães, Mohammadreza Esmaeili Dooki, Mahmoud Hajipour, Farid Imanzadeh
Gastroenterology & Endoscopy.2025;[Epub] CrossRef
Crohn’s disease in patients with Hirschsprung disease and Hirschsprung-associated enterocolitis: A review
Victoria A. Glushkova, Aleksey V. Podkamenev, Tatyana V. Gabrusskaya
Russian Journal of Pediatric Surgery, Anesthesia and Intensive Care.2024; 14(1): 97. CrossRef
Transcriptome profiling of intact bowel wall reveals that PDE1A and SEMA3D are possible markers with roles in enteric smooth muscle apoptosis, proliferative disorders, and dysautonomia in Crohn’s disease
Yun Yang, Lin Xia, Wenming Yang, Ziqiang Wang, Wenjian Meng, Mingming Zhang, Qin Ma, Junhe Gou, Junjian Wang, Ye Shu, Xiaoting Wu
Frontiers in Genetics.2023;[Epub] CrossRef
A unicentric cross-sectional observational study on chronic intestinal inflammation in total colonic aganglionosis: beware of an underestimated condition
M Erculiani, F Poluzzi, G Mottadelli, E Felici, Novi ML, M Caraccia, A Grandi, S Casella, L Giacometti, G Montobbio, I Ceccherini, E Di Marco, C Bonaretti, R Biassoni, M Squillario, A Pietrantoni, V Villanacci, A Pini Prato
Orphanet Journal of Rare Diseases.2023;[Epub] CrossRef
Clinical characteristics and validation of diagnosis in individuals with Hirschsprung disease and inflammatory bowel disease
Anna Löf Granström, Jonas F Ludvigsson, Tomas Wester
Journal of Pediatric Surgery.2021; 56(10): 1799. CrossRef
Crohn-Like Colitis in a Young Boy With Hirschsprung Disease
Alessandra Verde, Angelina Grammegna, Emma Petrone, Augusto Mastrominico, Daniele De Brasi, Claudia Mandato, Giusy Ranucci, Maria Simona Sabbatino, Michelina Sibilio, Paolo Quitadamo
Inflammatory Bowel Diseases.2021; 27(9): e112. CrossRef
Inflammatory bowel disease in patients with Hirschsprung’s disease: a systematic review and meta-analysis
H. Nakamura, T. Lim, P. Puri
Pediatric Surgery International.2018; 34(2): 149. CrossRef
Increased Risk of Inflammatory Bowel Disease in a Population‐based Cohort Study of Patients With Hirschsprung Disease
Anna Löf Granström, Leila Amin, Henrik Arnell, Tomas Wester
Journal of Pediatric Gastroenterology and Nutrition.2018; 66(3): 398. CrossRef

7,739 View
70 Download
8 Web of Science
8 Crossref

First
Prev
Page of 1
Next
Last

Search